One potential complication was first reported in July 2024 when a study found people using semaglutide were at a Now, a new study recently published in the journal For this study, researchers analyzed health records from 2020 to 2023 of more than 139,000 Ontario residents with an average age of 66 and diagnosis of diabetes
(2019, February 26)
Several other trials are assessing the safety and efficacy of tirzepatide in improving different cardiometabolic complications such as OSA, MASH and heart failure with preserved ejection fraction (HFpEF) (NCT05412004, NCT04166773, NCT 04847557) [16]
For patients living with obesity, diabetes, or established cardiovascular disease, that distinction matters enormously
Logistic regression to evaluate the influence of age, sex, and weight